IFIH1 and dermatomyositis: Anti-MDA5 dermatomyositis constitutes a rare but clinically significant subtype of inflammatory myopathy, distinguished by its unique presentation of characteristic cutaneous manifestations, minimal or absent muscle involvement, and a disproportionately high risk of developing rapidly progressive interstitial lung disease (RP-ILD) [3,4].